Assistant Prof. PharmDr. Jan Miroslav Hartinger, Ph.D.
· Born on 30th August 1983 in Hradec Králové, Czech Republic
· Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague
· Tel. +420 22496 4136
Research focus
· Pharmacokinetics in patients with altered renal functions (decreased eGFR, proteinuria, hemodialysis, peritoneal dialysis)
· Pharmacokinetics in obesity and after bariatry/metabolic surgery
· Pharmacology of monoclonal antibodies and fusion proteins
· Drug interactions with components of tobacco smoke
Education
- PhD: Biology and Pathology of Cell, First Faculty of Medicine, Charles University in Prague. Thesis: Molecular basis of fluoropyrimidine toxic effect etiology with focus on palmar-plantar erythrodysesthesia and potential antidote use
- 2008 graduated from Faculty of Pharmacy in Hradec Králové, Charles University in Prague
Specialization (Board certification)
· 2015 – Clinical Pharmacy
Professional membership
· Czech Society of Clinical Pharmacy CzMA JEP
· Czech Society for Experimental and Clinical Pharmacology and Toxicology
· Czech Society of Nephrology CzMA JEP
· European Renal Association – European Dialysis and Transplantation Association (ERA-EDTA)
Awards/Prizes
· Award of the Czech Society for Tobacco Addiction Treatment for propagation of tobacco addiction treatment in the field of pharmacology
Publications
1. Hartinger JM, Šíma M, Hrušková Z, Pilková A, Krátký V, Ryšavá R, et al. A novel dosing approach for rituximab in glomerular diseases based on a population pharmacokinetic analysis. Biomed Pharmacother. 2024;175:116655. (IF 2022 = 7,5)
2. Hartinger JM, Dvořáčková E, Krátký V, Hrušková Z, Mysliveček M, Bobek D, et al. Elimination and penetration of Amikacin into urine in patients with decreased glomerular filtration rate. Clinical Kidney Journal. 2024:sfae002. (IF 2022 = 4,6)
3. Hartinger JM, Šíma M, Hronová K, Halouzková BA, Szonowská B, Polakovič V, et al. Vancomycin pharmacokinetics in patients treated with intermittent haemodialysis based on therapeutic drug monitoring. J Chemother. 2021:1-8. (IF 2021 = 2,4)
4. Hartinger JM, Michaličková D, Dvořáčková E, Hronová K, Krekels EHJ, Szonowská B, et al. Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications. Pharmaceutics [Internet]. 2023; 15(5) . (IF 2022 = 5,4)
5. Michaličková D, Hartinger JM (sdílené prvoautorství), Hladinová Z, Bednářová V, Szonowská B, Polakovič V, et al. Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy. Eur J Clin Pharmacol. 2021. (IF 2021 = 2,9)
6. Sima M, Hartinger J, Stenglova Netikova I, Slanar O. Creatinine Clearance Estimations for Vancomycin Maintenance Dose Adjustments. Am J Ther. 2017. (IF 2017 = 1,0)
7. Sima M, Hartinger J, Cikankova T, Slanar O. Estimation of once-daily amikacin dose in critically ill adults. J Chemother. 2017:1-7. (IF 2017 = 1,5)
8. Šíma M, Hartinger J, Grus T, Slanař O. Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function. European Journal of Hospital Pharmacy. 2019:ejhpharm-2019-002013. (IF 2017 = 0,9)
9. Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022;13:1024068. (IF 2022 = 7,3)
10. Halouzková BA, Hartinger JM (korespondenční autor), Krátký V, Tesař V, Slanař O. Dosing of Aminoglycosides in Chronic Kidney Disease and End-Stage Renal Disease Patients Treated with Intermittent Hemodialysis. Kidney Blood Press Res. 2022;47(7):448-58. (IF 2022 = 2,8)
11. Hartinger JM, Satrapová V, Hrušková Z, Tesař V. Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. European Journal of Hospital Pharmacy. 2018. (IF 2022 = 0,7)
12. Maixnerova D, Hartinger J, Tesar V. Expanding options of supportive care in IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii47-ii54. (IF 2022 = 4,6)
13. Sima M, Hartinger J, Cikankova T, Slanar O. Importance of vancomycin loading doses in intermittent infusion regimens. J Infect Chemother. 2018;24(4):247-50. (IF 2018 = 1,5)
14. Šíma M, Bakhouche H, Hartinger J, Cikánková T, Slanař O. Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. European Journal of Hospital Pharmacy. 2019;26(2):85. (IF 2019 = 0,9)
15. Sima M, Hronova K, Hartinger J, Slanar O. A simulation of loading doses for vancomycin continuous infusion regimens in intensive care. Infect Dis (Lond). 2017;49(9):674-9. (IF 2017 = 1,9)
16. Sima M, Pokorna P, Hartinger J, Slanar O. Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. J Clin Pharm Ther. 2017. (IF 2017 = 1,7)
17. Šíma M, Michaličková D, Ryšánek P, Cihlářová P, Kuchař M, Lžičařová D, et al. No Time Dependence of Ciprofloxacin Pharmacokinetics in Critically Ill Adults: Comparison of Individual and Population Analyses. Pharmaceutics. 2021;13(8). (IF 2021 = 6,5)
18. Michaličková D, Jansa P, Bursová M, Hložek T, Čabala R, Hartinger JM, et al. Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice. Pulm Circ. 2020;10(1):2045894019898031. (IF 2020 = 3,0)
19. Hartinger JM, Ryšánek P, Slanař O, Šíma M. Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients. J Clin Pharm Ther. 2022;47(9):1362-7. (IF 2022 = 2,0)
20. Dvořáčková E, Pilková A, Matoulek M, Slanař O, Hartinger JM. Bioavailability of Orally Administered Drugs After Bariatric Surgery. Current Obesity Reports. 2024 (IF 2022 = 8,8)
21. Hartinger J, Novotny R, Bilkova J, Kvasnicka T, Mitas P, Sima M, et al. Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation. Med Princ Pract. 2018;27(4):356-61. (IF 2018 = 1,1)
22. Hartinger JM, Svobodová A, Malíková I, Šachl R, Slanař O. Effective use of fondaparinux in patient with unresponsiveness to nadroparin. J Clin Pharm Ther. 2020. (IF 2020 = 2,5)
23. Hartinger JM, Dvorackova E, Myslivecek M, Hruskova Z, Satny M, Zlatohlavek L, et al. The frequency of, and predisposing risk factors for, ciprofloxacin-induced neuro-psychiatric adverse drug reactions. Bratisl Lek Listy. 2023;124(10):779-82. (IF 2022 = 1,5)
24. Nikrýnová Nguyen TMP, Štrauch B, Petrák O, Krátká Z, Holaj R, Kurcová I, et al. Adherence and blood pressure control in patients with primary aldosteronism. Blood Press. 2022;31(1):58-63. (IF 2022 = 1,8)
25. Pilkova A, Sima M, Hartinger JM, Nikrynova Nguyen TMP, Maresova V, Kurcova I, et al. Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. (IF 2022 = 0,9)
26. Lukáč P, Hartinger JM (korespondenční autor), Mlček M, Popková M, Suchý T, Šupová M, et al. A novel gentamicin-releasing wound dressing prepared from freshwater fish Cyprinus carpio collagen cross-linked with carbodiimide. Journal of Bioactive and Compatible Polymers. 2019:0883911519835143. (IF 2019 = 1,6)
27. Hartinger JM, Lukac P, Mitas P, Mlcek M, Popkova M, Suchy T, et al. Vancomycin-releasing cross-linked collagen sponges as wound dressings. Bosn J Basic Med Sci. 2019. (IF 2019 = 2,1)
28. Hartinger JM, Lukáč P, Mlček M, Popková M, Suchý T, Šupová M, et al. Rifampin-Releasing Triple-Layer Cross-Linked Fresh Water Fish Collagen Sponges as Wound Dressings. Biomed Res Int. 2020;2020:3841861. (IF 2020 = 3,4)
29. Hartinger J, Vesely P, Netikova I, Matouskova E, Petruzelka L. The protective effect of pyrimidine nucleosides on human HaCaT keratinocytes treated with 5-FU. Anticancer Res. 2015;35(3):1303-10. (IF 2015 = 1,9)
30. Hartinger J, Vesely P, Matouskova E, Argalacsova S, Petruzelka L, Netikova I. Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT. ScientificWorldJournal. 2012;2012:421325.
31. Hartinger J, Vesely P, Sima M, Netikova I, Matouskova E, Petruzelka L. 5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line. Prague Med Rep. 2017;118(4):128-38.